4 Healthcare Stock Stories for Investors to Take Daily

Pfizer (NYSE:PFE): Closing price $26.76

Pfizer might request an expedited review from the FDA for its treatment to slow a type of incurable breast cancer which is currently in Phase 2 trial, said Bloomberg, citing statements of Mikael Dolsten, head of worldwide research, who said at a JPMorgan conference that the firm has not yet reached a decision but is “obviously open to dialogues and advice from FDA and the European agencies regarding getting the drug to patients as soon as possible.”